Patents by Inventor Isabelle Navarro-Teulon

Isabelle Navarro-Teulon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF MÜLLERIAN INHIBITING SUBSTANCE INHIBITORS FOR TREATING CANCER
    Publication number: 20220290151
    Abstract: In ovarian carcinoma, Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway are potential therapeutic targets. Conversely, the role of the three MIS type I receptors (MISRI; ALK2, ALK3 and ALK6) in this cancer needs to be clarified. Using four ovarian cancer cell lines and ovarian cancer cells isolated from patients' tumor ascites, the inventors found that ALK2 and ALK3 are the two main MISRIs involved in MIS signaling at low and high MIS concentrations, respectively. Moreover, high MIS concentrations were associated with apoptosis and decreased clonogenic survival, whereas low MIS concentrations improved cancer cell viability. Finally, the inventors showed that MIS siRNA inhibited MIS pro-survival effect. These last results open the way to an innovative therapeutic approach to suppress MIS proliferative effect, instead of administering high doses of MIS to induce cancer cell apoptosis.
    Type: Application
    Filed: September 25, 2020
    Publication date: September 15, 2022
    Inventors: Andre PELEGRIN, Thierry CHARDES, Isabelle NAVARRO-TEULON, Maeva CHAUVIN
  • Pharmaceutical compositions comprising an antibody which binds the human anti-Müllerian hormone receptor type II
    Patent number: 10179816
    Abstract: The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: January 15, 2019
    Assignees: LABOTATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, ICM INSTITUT REGIONAL DU CANCER DE MONTPELLIER, I.N.S.E.R.M. (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER
    Inventors: Christine Gaucher, Isabelle Navarro-Teulon
  • Mutated humanized 12G4 antibodies and the fragments thereof against the human anti-Mullerian hormone receptor type II
    Patent number: 9637544
    Abstract: Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: May 2, 2017
    Assignees: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, UNIVERSITE MONTPELLIER I, CENTRE NATIONAL DE LUTTE CONTRE LE CANCER, I.N.S.E.R.M. (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Christian Behrens, Isabelle Navarro-Teulon
  • NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIBODY WHICH BINDS THE HUMAN ANTI-MÜLLERIAN HORMONE RECEPTOR TYPE II
    Publication number: 20170101478
    Abstract: The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions.
    Type: Application
    Filed: October 25, 2016
    Publication date: April 13, 2017
    Inventors: Christine GAUCHER, Isabelle NAVARRO-TEULON
  • Pharmaceutical compositions comprising an antibody which binds the human anti-mullerian hormone receptor type II
    Patent number: 9511138
    Abstract: The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: December 6, 2016
    Assignees: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, CENTRE REGIONAL DE LUTTE CONTRE LE CANCER, I.N.S.E.R.M. (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE MONTPELLIER 1
    Inventors: Christine Gaucher, Isabelle Navarro-Teulon
  • NOVEL MUTATED HUMANIZED 12G4 ANTIBODIES AND THE FRAGMENTS THEREOF AGAINST THE HUMAN ANTI-MULLERIAN HORMONE RECEPTOR TYPE II
    Publication number: 20150232563
    Abstract: Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor.
    Type: Application
    Filed: March 16, 2015
    Publication date: August 20, 2015
    Inventors: Christian BEHRENS, Isabelle NAVARRO-TEULON
  • Mutated humanized 12G4 antibodies and the fragments thereof against the human anti-Mullerian hormone receptor type II
    Patent number: 9012607
    Abstract: Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: April 21, 2015
    Assignees: Laboratoire Francais du Fractionnement et des Biotechnologies, Universite Montpellier I, Centre National de Lutte Contre le Cancer, I.N.S.E.R.M. (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Christian Behrens, Isabelle Navarro-Teulon
  • NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIBODY WHICH BINDS THE HUMAN ANTI-MULLERIAN HORMONE RECEPTOR TYPE II
    Publication number: 20150004156
    Abstract: The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 1, 2015
    Applicants: LABORATOIRES FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, CENTRE NATIONAL DE LUTTE CONTRE LE CANCER, I.N.S.E.R.M. (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE MONTPELLIER 1
    Inventors: Christine Gaucher, Isabelle Navarro-Teulon
  • NOVEL MUTATED HUMANIZED 12G4 ANTIBODIES AND THE FRAGMENTS THEREOF AGAINST THE HUMAN ANTI-MULLERIAN HORMONE RECEPTOR TYPE II
    Publication number: 20130136743
    Abstract: Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor.
    Type: Application
    Filed: April 1, 2011
    Publication date: May 30, 2013
    Applicants: LFB BIOTECHNOLOGIES, I.N.S.E.R.M. (Institut National de la Sante et de Recherche Medicale), CENTRE NATIONAL DE LUTTE CONTRE LE CANCER, UNIVERSITE MONTPELLIER I
    Inventors: Christian Behrens, Isabelle Navarro-Teulon
  • BRIEF RADIOIMMUNOTHERAPY
    Publication number: 20120308477
    Abstract: The present invention relates to a method of treating a subject having a cancer in a body cavity characterized in that it comprises the steps of: administering in said body cavity of the subject radiolabeled binding molecules which bind to an antigen expressed by cancerous cells; washing the body cavity to remove unbound radiolabeled molecules. The present invention also relates to a body cavity perfusing system for carrying out said method.
    Type: Application
    Filed: May 30, 2011
    Publication date: December 6, 2012
    Inventors: Vincent BOUDOUSQ, Isabelle Navarro-Teulon, Jean-Pierre Pouget, Andre Pelegrin